Prior Stephen David 4
4 · AN2 Therapeutics, Inc. · Filed Nov 6, 2025
Insider Transaction Report
Form 4
Prior Stephen David
Chief Strategy Officer
Transactions
- Sale
Common Stock
2025-11-04$1.14/sh−765$872→ 65,548 total
Footnotes (3)
- [F1]Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on November 4, 2025.
- [F2]Includes, in accordance with the original terms, (a) 10,125 RSUs which shall vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024 and (b) 12,031 RSUs which shall vest on January 1, 2026, in each case, subject to the Reporting Person continuing to provide services to the Company as an employee, consultant or director of the Company through each applicable vesting date.
- [F3]Reflects the adjusted total which includes the purchase of 5,000 shares under the Issuer's 2022 Employee Stock Purchase Plan on September 30, 2025.